IonQ Unveils Its First Quantum Computer in Europe, Online Now at a Record #AQ36
5.12.2024 14:05:00 CET | Business Wire | Press release
IonQ’s quantum computer Forte Enterprise has achieved the record-breaking milestone of #AQ36In partnership with QuantumBasel, IonQ Forte Enterprise will provide European Enterprise Customers, Industries, government entities, and research institutes with local access to IonQ’s most powerful quantum systemsIonQ has opened its First European Innovation Center at the uptownBasel campus in Arlesheim, Switzerland
IonQ (NYSE: IONQ), a leader in the quantum computing and networking industry, today announced the delivery of IonQ Forte Enterprise to its first European Innovation Center at the uptownBasel campus in Arlesheim, Switzerland. Achieved in partnership with QuantumBasel, this major milestone marks the first datacenter-ready quantum computer IonQ has delivered that will operate outside the United States and the first quantum system for commercial use in Switzerland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241205805000/en/

IonQ European Innovation Center - Arlesheim, Switzerland (Photo: Business Wire)
Forte Enterprise is now online servicing compute jobs while performing at a record algorithmic qubit count of #AQ36, which is significantly more powerful than the promised #AQ35. With each additional #AQ, the useful computational space for running quantum algorithms doubles. A system with #AQ36 is capable of considering more than 68 billion different possibilities simultaneously. With this milestone, IonQ once again leads the industry in delivering production-ready systems to customers.
“The successful commissioning of Forte Enterprise in Europe – on schedule and at an even higher performance level than announced previously – demonstrates IonQ’s commitment to driving global quantum adoption through technological leadership and operational excellence,” said Peter Chapman, CEO and President of IonQ. “Achieving #AQ36 is a significant leap forward, opening new possibilities for applications including logistics, finance, pharmaceuticals, chemistry and artificial intelligence.”
“Offering the state-of-the-art Forte Enterprise quantum computing platform to our ecosystem will accelerate the development of quantum applications across a range of fields,” said Damir Bogdan, CEO of QuantumBasel. “By collaborating with IonQ, we’re positioning the uptownBasel campus as a leader in quantum innovation, fostering breakthroughs that address real-world challenges.”
IonQ’s next generation commercial quantum systems such as Forte Enterprise are optimized for data center environments, sporting a rack-mounted form factor, low energy profile, and minimal environmental isolation requirements.
Building on a History of Excellence
Today’s IonQ Forte Enterprise system commissioning represents the culmination of IonQ’s engineering innovation, operational excellence, and enterprise-grade production capabilities.
“This milestone reflects the hard work and ingenuity of teams across IonQ and QuantumBasel,” said Dr. Dave Mehuys, VP of Production Engineering. “We aligned our system build with on-site datacenter construction and IonQ’s manufacturing and production teams leveraged their decades of expertise to bring this groundbreaking system online faster than anticipated.”
Pioneering a New Era of Computing
IonQ’s record-breaking achievement of #AQ36 signals the company’s dedication and success in advancing quantum performance. Forte Enterprise expands the potential for driving groundbreaking research in areas such as quantum chemistry and machine learning.
“IonQ’s ability to deliver Forte Enterprise with #AQ36 reflects our growing capabilities to execute on our mission to drive significant quantum advancements globally,” said Dr. Dean Kassmann, Senior Vice President of Engineering and Technology at IonQ. “Each step we take demonstrates our commitment to bringing quantum computing from the lab to practical, impactful, and commercial uses.”
A Quantum Leap for Europe and Beyond
IonQ’s first European Innovation Center will allow the company to service its European customers out of its QuantumBasel location and to drive research and development of next generation quantum applications in Europe.
As part of its partnership with IonQ, QuantumBasel will offer its ecosystem– including enterprises, research institutes, startups, and universities – direct access to the #AQ36 Forte Enterprise system.
With datacenters now in the Washington, D.C., Seattle, and Basel, Switzerland areas, IonQ has firmly established a global data center footprint, reinforcing its position as a leader in quantum technology.
To learn more about IonQ’s latest innovations, visit www.ionq.com.
About IonQ
IonQ, Inc. is a leader in quantum computing that delivers high-performance systems capable of solving the world’s largest and most complex commercial and research use cases. IonQ’s current generation quantum computer, IonQ Forte, is the latest in a line of cutting-edge systems, boasting 36 algorithmic qubits. The company’s innovative technology and rapid growth were recognized in Fast Company’s 2023 Next Big Things in Tech List and Deloitte’s 2023 Technology Fast 500™ List, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ.com.
About QuantumBasel
QuantumBasel is a competence center for quantum computing and AI and drives access to commercial quantum computing to foster innovation. QuantumBasel places particular emphasis on technological neutrality and is Switzerland’s first commercial quantum computing hub, providing access to hardware from IBM, D-Wave and IonQ. QuantumBasel’s team of quantum and data scientists trains and supports companies, conducts projects in quantum computing and AI, and collaborates closely with universities and academic institutions. Through an internationally connected ecosystem, QuantumBasel provides access to advanced know-how and technologies, enabling companies in industrial production, logistics, finance, energy, life sciences, and start-ups to achieve innovations they cannot develop independently. www.quantumbasel.com
IonQ Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the terms “adoption,” “advancing,” “advancements,” “collaborating,” “commitment,” “demonstrates,” “development,” “groundbreaking” “milestone,” “next generation,” “optimized,” “potential,” “significant leap forward,” “state-of-the-art,” “will,” and other similar expressions are intended to identify forward-looking statements. These statements include those related to the company’s technology driving commercial quantum advantage in the future, the timing of delivering to customers IonQ Forte Enterprise systems, the planned increase to the footprint of the uptownBasel campus in Arlesheim, Switzerland, the company’s ability to establish public-private partnerships, the ability for third parties to implement IonQ’s offerings to increase their quantum computing capabilities, access to IonQ’s quantum computers, the ability to test and execute quantum applications on IonQ’s quantum computers, the opportunity to test and optimize novel quantum-enhanced algorithms for computational challenges on IonQ’s quantum computers; the problems that can be solved by IonQ’s quantum computers, the advantages of IonQ's approach to the manufacturing of IonQ’s systems, IonQ’s quantum computing capabilities and plans, and the scalability and reliability of IonQ’s quantum computing offerings. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: changes in the competitive industries in which IonQ operates; the ability of IonQ to protect its intellectual property; changes in laws and regulations affecting IonQ’s business; IonQ’s ability to implement its business plans, technical roadmap, and other expectations, identify and realize partnerships and opportunities, and to engage new and existing customers; or market adoption of quantum computing solutions and IonQ’s products, services and solutions. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company’s filings, including but not limited to those described in the “Risk Factors” section of IonQ’s most recent Quarterly Report on Form 10-Q and other documents filed by IonQ from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations. IonQ may or may not choose to practice or otherwise use the inventions described in the issued patents in the future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205805000/en/


Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom